阿帕替尼治疗碘难治性分化型甲状腺癌的可行性。
Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma.
机构信息
Department of Head Neck and Thyroid, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
Department of Breast and Thyroid Surgery, People's Hospital of Changshou District, Chongqing, China.
出版信息
Front Endocrinol (Lausanne). 2022 Feb 23;13:768028. doi: 10.3389/fendo.2022.768028. eCollection 2022.
OBJECTIVES
Our aim was to describe our experience in using apatinib as treatment for radioiodine-refractory differentiated thyroid carcinoma (RAIR-DTC).
METHODS
Forty-seven patients undergoing apatinib treatment for RAIR-DTC were prospectively enrolled in this study. The study endpoints were objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and rate of adverse events.
RESULTS
No patients achieved complete response, while 36 (76.6%) and 8 (17.0%) patients achieved partial response and stable disease, respectively. The ORR and DCR were 76.6% and 93.6%, respectively. The median PFS and OS were 18 and 59 months, respectively. A total of 91 adverse events occurred, of which 21 were graded as grade 3 or higher. There were no drug-related deaths.
CONCLUSIONS
Apatinib has distinct anti-RAIR-DTC efficacy in terms of ORR, PFS, and OS and has a favorable safety profile. It is a feasible treatment option for RAIR-DTC.
目的
我们旨在描述使用阿帕替尼治疗放射性碘难治性分化型甲状腺癌（RAIR-DTC）的经验。
方法
本研究前瞻性纳入了 47 例接受阿帕替尼治疗的 RAIR-DTC 患者。研究终点为客观缓解率（ORR）、疾病控制率（DCR）、无进展生存期（PFS）、总生存期（OS）和不良事件发生率。
结果
无患者达到完全缓解，而 36 例（76.6%）和 8 例（17.0%）患者分别达到部分缓解和疾病稳定。ORR 和 DCR 分别为 76.6%和 93.6%。中位 PFS 和 OS 分别为 18 个月和 59 个月。共发生 91 例不良事件，其中 21 例为 3 级或更高。无药物相关死亡。
结论
阿帕替尼在 ORR、PFS 和 OS 方面具有明显的抗 RAIR-DTC 疗效，且安全性良好。它是 RAIR-DTC 的一种可行的治疗选择。
Zotero 插件